Literature DB >> 26055375

Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance.

Susanne Schmidt1, Kathrin Bohn-Wippert1, Peter Schlattmann2, Roland Zell1, Andreas Sauerbrei3.   

Abstract

A total of 302 clinical herpes simplex virus 1 (HSV-1) strains, collected over 4 decades from 1973 to 2014, were characterized retrospectively for drug resistance. All HSV-1 isolates were analyzed genotypically for nonsynonymous mutations in the thymidine kinase (TK) and DNA polymerase (Pol) genes. The resistance phenotype against acyclovir (ACV) and/or foscarnet (FOS) was examined in the case of novel, unclear, or resistance-related mutations. Twenty-six novel natural polymorphisms could be detected in the TK gene and 69 in the DNA Pol gene. Furthermore, three novel resistance-associated mutations (two in the TK gene and one in the DNA Pol gene) were analyzed, and eight known but hitherto unclear amino acid substitutions (two encoded in TK and six in the DNA Pol gene) could be clarified. Between 1973 and 2014, the distribution of amino acid changes related to the natural gene polymorphisms of TK and DNA Pol remained largely stable. Resistance to ACV was confirmed phenotypically for 16 isolates, and resistance to ACV plus FOS was confirmed for 1 isolate. Acyclovir-resistant strains were observed from the year 1995 onwards, predominantly in immunosuppressed patients, especially those with stem cell transplantation, and the number of ACV-resistant strains increased during the last 2 decades. The data confirm the strong genetic variability among HIV-1 isolates, which is more pronounced in the DNA Pol gene than in the TK gene, and will facilitate considerably the rapid genotypic diagnosis of HSV-1 resistance.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26055375      PMCID: PMC4505214          DOI: 10.1128/AAC.00977-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

Review 1.  Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Resistance of herpes simplex virus type 1 to acyclovir: thymidine kinase gene mutagenesis study.

Authors:  Emilie Frobert; Tadamasa Ooka; Jean-Claude Cortay; Bruno Lina; Danielle Thouvenot; Florence Morfin
Journal:  Antiviral Res       Date:  2006-08-30       Impact factor: 5.970

3.  Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients.

Authors:  A Gaudreau; E Hill; H H Balfour; A Erice; G Boivin
Journal:  J Infect Dis       Date:  1998-08       Impact factor: 5.226

Review 4.  Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms.

Authors:  Christian Gilbert; Julie Bestman-Smith; Guy Boivin
Journal:  Drug Resist Updat       Date:  2002-04       Impact factor: 18.500

5.  Longitudinal Characterization of Herpes Simplex Virus (HSV) Isolates Acquired From Different Sites in an Immune-Compromised Child: A New HSV Thymidine Kinase Mutation Associated With Resistance.

Authors:  Andrew H Karaba; Laura K Cohen; Taly Glaubach; Sarah J Kopp; Jennifer L Reichek; Hawke H Yoon; Xiaotian T Zheng; William J Muller
Journal:  J Pediatric Infect Dis Soc       Date:  2012-05-03       Impact factor: 3.164

6.  Resistance of herpes simplex viruses to acyclovir: an update from a ten-year survey in France.

Authors:  Emilie Frobert; Sonia Burrel; Sophie Ducastelle-Lepretre; Geneviève Billaud; Florence Ader; Jean-Sébastien Casalegno; Viviane Nave; David Boutolleau; Mauricette Michallet; Bruno Lina; Florence Morfin
Journal:  Antiviral Res       Date:  2014-09-08       Impact factor: 5.970

7.  Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up.

Authors:  C Danve-Szatanek; M Aymard; D Thouvenot; F Morfin; G Agius; I Bertin; S Billaudel; B Chanzy; M Coste-Burel; L Finkielsztejn; H Fleury; T Hadou; C Henquell; H Lafeuille; M E Lafon; A Le Faou; M C Legrand; L Maille; C Mengelle; P Morand; F Morinet; E Nicand; S Omar; B Picard; B Pozzetto; J Puel; D Raoult; C Scieux; M Segondy; J M Seigneurin; R Teyssou; C Zandotti
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

8.  Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: report on a two-year sensitivity screening survey.

Authors:  F Nugier; J N Colin; M Aymard; M Langlois
Journal:  J Med Virol       Date:  1992-01       Impact factor: 2.327

9.  Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir.

Authors:  P Collins; M N Ellis
Journal:  J Med Virol       Date:  1993       Impact factor: 2.327

10.  Related functional domains in virus DNA polymerases.

Authors:  B A Larder; S D Kemp; G Darby
Journal:  EMBO J       Date:  1987-01       Impact factor: 11.598

View more
  11 in total

Review 1.  Herpes Genitalis: Diagnosis, Treatment and Prevention.

Authors:  A Sauerbrei
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-10-18       Impact factor: 2.915

2.  Acyclovir resistance in herpes simplex virus type I encephalitis: a case report.

Authors:  Andreas Sauerbrei
Journal:  J Neurovirol       Date:  2017-06-21       Impact factor: 2.643

3.  Severe acyclovir-resistant herpes simplex virus 1 infection following cord blood transplantation.

Authors:  Tomonari Shigemura; Yozo Nakazawa; Tomoki Yoshikawa; Hikaru Fujii; Souichi Yamada; Masayuki Saijo; Ryuhei Okuyama
Journal:  Int J Hematol       Date:  2018-06-19       Impact factor: 2.490

4.  Differences in the Likelihood of Acyclovir Resistance-Associated Mutations in the Thymidine Kinase Genes of Herpes Simplex Virus 1 and Varicella-Zoster Virus.

Authors:  Hikaru Fujii; Shizuko Harada; Tomoki Yoshikawa; Souichi Yamada; Natsumi Omura; Miho Shibamura; Takuya Inagaki; Hirofumi Kato; Shuetsu Fukushi; Masayuki Saijo
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

5.  The HIV Integrase Inhibitor Raltegravir Inhibits Felid Alphaherpesvirus 1 Replication by Targeting both DNA Replication and Late Gene Expression.

Authors:  Matthew R Pennington; Ian E H Voorhees; Heather M Callaway; Shannon D Dehghanpir; Joel D Baines; Colin R Parrish; Gerlinde R Van de Walle
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

Review 6.  Optimal management of genital herpes: current perspectives.

Authors:  Andreas Sauerbrei
Journal:  Infect Drug Resist       Date:  2016-06-13       Impact factor: 4.003

7.  Herpes Simplex Virus Type 1 Clinical Isolates Respond to UL29-Targeted siRNA Swarm Treatment Independent of Their Acyclovir Sensitivity.

Authors:  Kiira Kalke; Jenni Lehtinen; Jelena Gnjatovic; Liisa M Lund; Marie C Nyman; Henrik Paavilainen; Julius Orpana; Tuomas Lasanen; Fanny Frejborg; Alesia A Levanova; Tytti Vuorinen; Minna M Poranen; Veijo Hukkanen
Journal:  Viruses       Date:  2020-12-13       Impact factor: 5.048

8.  Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus.

Authors:  Yuko Sato; Tadahiro Suenaga; Makoto Kobayashi; Nozomu Miyazaki; Takato Suzuki; Ken Ishioka; Tatsuo Suzutani
Journal:  Antimicrob Agents Chemother       Date:  2021-07-06       Impact factor: 5.191

9.  Recombinant herpes simplex virus type 1 strains with targeted mutations relevant for aciclovir susceptibility.

Authors:  Anne-Kathrin Brunnemann; Kristin Liermann; Stefanie Deinhardt-Emmer; Gregor Maschkowitz; Anja Pohlmann; Beate Sodeik; Helmut Fickenscher; Andreas Sauerbrei; Andi Krumbholz
Journal:  Sci Rep       Date:  2016-07-18       Impact factor: 4.379

Review 10.  The three-component helicase/primase complex of herpes simplex virus-1.

Authors:  Oya Bermek; R Scott Williams
Journal:  Open Biol       Date:  2021-06-09       Impact factor: 6.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.